Fundraising FoxWuXi Healthcare Ventures
Venture capitalGrand Cayman · 2 people tracked
Find your way into WuXi Healthcare Ventures
Each arrow is one introduction. Sign up to fill in the first one.
Ask James Huang to introduce you to Fay Xing
You →James · together at Panacea Venture →Fay
Ask Jamie Chen to introduce you to Wei Li
You →Jamie · together at Quantxbio →Wei
Sign up to find every way you can get introduced to WuXi Healthcare Ventures
- Your email: who you already know at WuXi Healthcare Ventures, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the WuXi Healthcare Ventures team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Fund manager profile
WuXi Healthcare Ventures is a venture fund manager based in Grand Cayman. SEC filings show 1 venture fund on record, most recently WuXi Healthcare Ventures II, L.P. ($250M offering) filed July 2015.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 2 people
from curatedWhat they invest in
from 6 of 8 portfolio companiesBiotech ×6Healthtech ×3Digital Health ×2Medical Devices ×2AI & Machine Learning ×1Deep Tech ×1Direct to Consumer ×1Longevity ×1
HQs:United States×7
Investments · 8 tracked
founders shown can be your intro pathBy year:2021 · 12018 · 12016 · 12015 · 22014 · 16 dated
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Paul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)
BoardTimothy Shannon(Director)inJohn Diekman(Director)inTerry Rosen(Director)Jeffrey Stein(Director)
Co-investors5AM VenturesCanaan PartnersGV (Google Ventures)Nextech InvestBiotechnology Value Fund
23andMe operates a research platform that collects genetic data from millions of users to advance genomic research and health discovery.
BiotechDigital HealthDirect to ConsumerHealthtechLongevityMountain View, US
Anne Wojcicki(CEO and Founder)inLinda Avey(Co-founder)Paul Cheung(Co-founder)Andrew Page(Executive Officer, Director)Kathy Hibbs(Executive Officer)in
BoardEsther Dyson(Director)in
Co-investorsAdam NashAllied Venture PartnersCivilization Ventures Management, LlcEQUIAMFirebolt Ventures Management Company, LlcG Squared+17 more
BiotechSan Diego, US
Francois Ferre(Director)Magda Marquet(Director)Jorge Garces(Executive Officer)inGreg Hamilton(Executive Officer, Director)Carin Sandvik(Executive Officer)Jeffrey G. Black(Executive Officer)
Co-investorsBioBritTelegraph Hill PartnersAlly Bridge GroupVivo Capital
Hong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.
Co-investorsARCH Venture Partners6 Dimensions CapitalBoyu CapitalGICHillhouse Capital
Ivenix makes an intelligent infusion pump system for hospital settings that delivers intravenous medications to patients while incorporating safeguards to reduce medication errors.
BiotechHealthtechMedical DevicesAmesbury, US
John Sokolowski(Executive Officer)inGeorge W. Gray(Executive Officer)Carolyn Malleck(Executive Officer)inJesse Ambrosina(Executive Officer)
BoardKetan Patel(Director)inJohn K. Clarke(Director)in
Co-investorsCardinal PartnersF-Prime CapitalSCP Vitalife PartnersECO Fleet Holdings
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.
BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)
Co-investorsARCH Venture PartnersGV (Google Ventures)RA CapitalAisling CapitalAlexandriaBezos Expeditions+7 more
BiotechMenlo Park, US
Cuiping Gu(Director)David Parkinson(Director)inZhenping Zhu(Director)Karen Liu(Director)Bing C. Wang(Executive Officer, Director)
Co-investorsDanhua CapitalSangel CapitalShangBay Capital LLC
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Cambridge, US
Nancy Simonian(CEO)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Exits · 4
3 IPOs · 1 acquisitions · showing 1Ideaya BiosciencesNASDAQ: IDYA
Portfolio news
latest coverage across their companies23andme · en.wikipedia.org · Sep 22, 2026
LifeMine Therapeutics · finsmes.com · Aug 8, 2026
Ivenix · trysignalbase.com · Mar 25, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Ideaya Biosciences | 5.4% | $10.00 | May 2019 | $10.5M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has WuXi Healthcare Ventures made?
- WuXi Healthcare Ventures has 8 tracked investments, 4 of which have exited.
- Where is WuXi Healthcare Ventures located?
- WuXi Healthcare Ventures is headquartered in Grand Cayman.